诺和诺德：欧盟委员会批准更高效剂量的Wegovy 注射液用于成人肥胖症治疗

Core Viewpoint - The European Commission has approved a new 7.2 mg weekly maintenance dose of Wegovy (semaglutide injection) for adult obesity patients, allowing EU doctors to prescribe this higher dosage for enhanced weight loss and muscle function maintenance [1] Group 1 - The approval allows for a prescription of 7.2 mg, which can be administered as three injections of 2.4 mg each, still maintaining a weekly injection schedule [1] - Novo Nordisk has submitted a marketing authorization application for the 7.2 mg single-dose injection pen in the EU, with potential approval and market launch expected this year [1] - In the EU, adult obesity patients can increase their dosage to 7.2 mg after using the 2.4 mg dose for at least four weeks to achieve greater weight loss [1] Group 2 - Wegovy 7.2 mg has already been approved and launched in the UK, while the FDA and other regulatory bodies in multiple countries are reviewing its registration applications [1]